Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Troubadour 

Sangamo Bioscienes diskutieren

Sangamo Therapeutics Inc.

WKN: 936386 / Symbol: SGMO / Name: Sangamo Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,38 €
-4,09 %

Einschätzung Buy
Rendite (%) -61,99 %
Kursziel 2,90
Veränderung
Endet am 31.12.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Jefferies Financial Group Inc. from $7.00 to $3.00. They now have a "buy" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -61,61 %
Kursziel 9,69
Veränderung
Endet am 02.01.26

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -65,71 %
Kursziel 4,80
Veränderung
Endet am 23.01.26

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Truist Financial Co. from $7.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -65,91 %
Kursziel 9,50
Veränderung
Endet am 27.01.26

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -37,99 %
Kursziel 9,11
Veränderung
Endet am 07.04.26

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -6,46 %
Kursziel 4,47
Veränderung
Endet am 14.05.26

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Barclays PLC from $9.00 to $5.00. They now have an "overweight" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,32 %
Kursziel 8,63
Veränderung
Endet am 24.06.26

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -15,68 %
Kursziel 8,58
Veränderung
Endet am 04.09.26

Sangamo Therapeutics (NASDAQ:SGMO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat